Flavonoid senolytic / mast cell stabilizer

Plain-language summaryIntrigue 62 / 100

Quercetin is a natural flavonoid found in onions, apples, and capers. It is one half of the dasatinib-quercetin (D+Q) senolytic combination. Quercetin alone has anti-allergic and anti-inflammatory effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

38/100

Established senolytic flavonoid with a real D+Q role but clearly outclassed by fisetin standing alone

Look, quercetin isn’t a bad compound. It’s just not a particularly exciting one right now, and the rubric rewards excitement. It’s a flavonoid you’ll find in every health food store, in onions, in apples. Researchers have been poking at it since the 1990s across allergy biology, NF-kB signaling, antioxidant assays, and a half-dozen other directions. None of those lines produced anything that made quercetin the center of a research program.

The senolytic angle changed the picture, a little. The Kirkland and Niedernhofer group’s work canonized the dasatinib-plus-quercetin (D+Q) regimen as the reference senolytic protocol, and that gave quercetin a specific, real identity in the aging research space. Small Mayo Clinic trials in idiopathic pulmonary fibrosis and diabetic kidney disease showed hints of a signal. The protocol is being used in ongoing NIA-funded trials. Thats genuinely meaningful. What we don’t like is that quercetin is the junior partner in that combination. Dasatinib is doing the mechanistic heavy lifting on the Bcl-2 and Bcl-xL senescence survival pathways. Quercetin contributes, but isolating its contribution from dasatinib in most D+Q datasets is difficult, and its standalone senolytic potency is explicitly weaker than fisetin in head-to-head comparisons.

The pharmacokinetics are a real problem for bench work. Oral bioavailability of the free aglycone is poor, with plasma concentrations after typical oral dosing well under one percent of the administered dose. Researchers working with quercetin in cell culture or preclinical models often dose at concentrations that don’t map cleanly to anything achievable in vivo. That gap creates a reproducibility problem that the literature is quietly littered with.

On mechanism, the multi-target profile sounds appealing: mast cell stabilization, NF-kB inhibition, antioxidant activity, Bcl-family modulation. In practice, that breadth is as much a research liability as an asset. When a compound does five things at once, attributing an effect to any one of them is methodologically hard. Most of the preclinical literature leans on this ambiguity rather than resolving it.

We think quercetin has a legitimate home in any senolytic research program as a reference tool and as the Q in D+Q studies. If you’re building a senolytic protocol from scratch and you’re not running D+Q specifically, fisetin is the more defensible choice at the bench right now. Quercetin isn’t junk. It’s an established, actively-studied compound with a real but secondary role in the most important research regimen in its class, and a score in the upper-30s reflects exactly that.

Novelty: 28
Mechanism promise: 45
In-category differentiation: 27
Evidence quality: 50
Translational signal: 40
Research bench value: 44

Rationale Quercetin escapes the OTC food/herb cap because the senolytic indication is a real, clinically-tested research angle with Mayo Clinic trials behind it, not a generic supplement claim. Scores land in the high-30s because the compound is genuinely useful within the D+Q protocol, but on every axis it’s the weaker partner: weaker senolytic than fisetin, poor oral bioavailability, and most of the clinical signal is inseparable from dasatinib’s contribution.

Flavonoid senolytic / mast cell stabilizer

A widely distributed flavonoid with weaker senolytic activity than fisetin, often combined with dasatinib in the canonical D+Q senolytic regimen.

Abstract

Quercetin (3,3′,4′,5,7-pentahydroxyflavone; CAS 117-39-5; molecular formula C15H10O7; molecular weight 302.24) is a widely distributed flavonoid present in onions, apples, capers, and many other plants. The compound has multiple mechanisms of pharmacological interest: mast cell stabilization (anti-allergic effects), direct antioxidant activity, anti-inflammatory effects through NF-kB inhibition, and senolytic activity (in combination with the kinase inhibitor dasatinib in the canonical D+Q regimen developed by Kirkland and Niedernhofer). The senolytic activity of quercetin alone is modest; the dasatinib combination is substantially more effective. Bioavailability is poor as the free aglycone but better as the rutinose glycoside; plasma quercetin concentrations after oral dosing are typically less than 1 percent of the dose. Doses range from 500 mg to 2 grams per day; the senolytic D+Q regimen uses pulsatile dosing of 1000 to 1500 mg quercetin with 100 mg dasatinib for 2 to 3 days monthly.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-100Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Flavonoid senolytic / mast cell stabilizer

Quercetin

Abstract

Read the full monograph